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Abstract Tumour necrosis factor (TNF)-related apoptosis-
inducing ligand (TRAIL) is a member of the TNF family of
cytokines that promotes apoptosis and NF-UB activation. Here
we show that recombinant hu-TRAIL initiates the activation of
multiple caspases, the loss of mitochondrial transmembrane
potential, the cleavage of BID and the redistribution of
mitochondrial cytochrome c. However, whereas Bcl-2 efficiently
blocked UV radiation-induced cytochrome c release and
consequent apoptosis of CEM cells, it failed to do either in the
context of TRAIL treatment. Thus, TRAIL engages a death
pathway that is at least partially routed via the mitochondria, but
in contrast with other stimuli that engage this pathway, TRAIL-
induced cytochrome c release is not regulated by Bcl-2.
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1. Introduction
Tumour necrosis factor (TNF)-related apoptosis-inducing
ligand (TRAIL) is a member of the TNF family of cytokines
that can promote apoptosis and NF-UB activation by binding
to the membrane receptors TRAIL-R1/death receptor (DR)4
and TRAIL-R2/DR5 [1^8]. Related TRAIL receptors
(TRAIL-R3/DcR1/TRID and TRAIL-R4/DcR2) have also
been described that do not promote apoptosis but may func-
tion as decoy receptors that reduce the amount of ligand
available for binding to TRAIL receptors 1 and 2 [5^12].
TRAIL induces apoptosis in a variety of transformed cell lines
but is far less e¡ective in promoting the death of untrans-
formed cells [13^15]. In addition, in contrast with the potent
cytotoxicity seen upon administration of agonistic anti-CD95
(APO-1/Fas) antibodies in mice [16], the administration of
leucine zipper forms of TRAIL is relatively non-toxic in
vivo [15]. Taken together, these observations suggest that
TRAIL may have considerable potential as a cancer therapeu-
tic agent.
The intracellular mechanism of TRAIL-induced apoptosis
is unclear at present. Predictably, TRAIL-induced apoptosis is
caspase-dependent but the repertoire and order of caspases
activated in response to TRAIL receptor engagement remain
ill-de¢ned [14,16^18]. Similarly, the adapter molecule(s) that
couple the cytoplasmic tail of the TRAIL receptors to the
death machinery has been the subject of debate
[3,5,10,17,19,20]. In particular, studies di¡er with respect to
the role of Fas-associated protein with death domain (FADD)
in transducing TRAIL receptor-initiated death signals
[3,5,10,17,19^21]. However, in this context it is relevant to
note that apoptosis in response to overexpression of
TRAIL-R1/DR4 remained intact in embryonic ¢broblasts
from FADD knockout mice, whereas CD95, TNFR1 and
DR3-initiated apoptosis were absent [22]. This suggests that
FADD is not essential for coupling TRAIL-R1 to the cyto-
plasmic e¡ectors of apoptosis but does not rule out the pos-
sibility that this adapter could participate in signalling events
initiated by TRAIL-R2/DR5 and even TRAIL-R1 in other
cell types.
In the context of other death receptors such as CD95 and
TNFR1, it has been established that caspase-8 is the most
proximally activated caspase within the death signalling path-
way [23^25]. Caspase-8 is thought to propagate the death
signal further in two alternative ways that are not necessarily
mutually exclusive: (1) by direct proteolytic processing of
downstream caspases such as caspase-3 [26^28] and (2) by
cleaving BID (a Bcl-2 family protein) which then targets the
mitochondria and promotes release of cytochrome c into the
cytosol [29^32]. Upon entry into the cytosol, cytochrome c
then propagates the caspase cascade by binding to Apaf-1
and activating its latent caspase-9 activating potential [33^
36]. Bcl-2 and Bcl-x have been shown to regulate the BID-
dependent pathway, but it is unclear whether they can also
intervene in the more direct mitochondria-independent path-
way [30^32].
To explore the mechanism of TRAIL-induced apoptosis, we
investigated the range of intracellular events that took place in
response to TRAIL receptor engagement in the Jurkat and
CEM T leukaemia cell lines. Exposure of Jurkat cells to re-
combinant TRAIL triggered apoptosis that was accompanied
by activation of multiple caspases, cleavage of several caspase
substrates, loss of mitochondrial transmembrane potential,
cleavage of BID, release of cytochrome c from the mitochon-
drial intermembrane space and exposure of phosphatidylser-
ine (PS) on the outer lea£et of the plasma membrane. Inter-
estingly, although Bcl-2 was e¡ective in attenuating BID
cleavage, cytochrome c release and consequent apoptosis in
response to UV irradiation, it failed to do so in the context of
TRAIL-induced apoptosis. These data suggest that TRAIL
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engages a Bcl-2-insensitive cell death pathway involving mito-
chondrial cytochrome c release.
2. Materials and methods
2.1. Materials
Annexin V-FITC was purchased from Clontech (Palo Alto, CA,
USA), 3,3P-dihexyloxacarbocyanine iodide (DiOC6) from Molecular
Probes (Eugene, OR, USA) and Z-Val-Ala-DL-Asp-£uoromethylke-
tone (z-VAD-fmk) from Bachem (UK). Anti-caspase-3 (CPP32),
anti-caspase-7 (Mch-3) and anti-gelsolin monoclonal antibodies
(mAbs) were purchased from Transduction Laboratories (Lexington,
KY, USA), anti-actin mAb from ICN (UK), anti-caspase-8 (FLICE)
and anti-caspase-6 mAbs from Pharmingen (San Diego, CA, USA),
anti-Fodrin mAb from Chemicon International (Temecula, CA,
USA), anti-caspase-2 (ICH-1S=L) polyclonal Ab from Santa Cruz
(Santa Cruz, CA, USA), anti-poly(ADP-ribose) polymerase (PARP)
polyclonal Ab from Boehringer Mannheim (Germany) and anti-
FLAG M2 mAb from Sigma (UK). Anti-caspase-9 rabbit polyclonal,
anti-FLICE/caspase-8 mAb, anti-BID rat polyclonal and anti-cyto-
chrome c rabbit polyclonal were generously provided by Dr Doug
Green (La Jolla Institute for Allergy and Immunology, San Diego,
CA, USA), Dr Marcus Peter (German Cancer Research Center, Tu-
mor Immunology Division, Heidelberg, Germany), Dr Junying Yuan
(Harvard Medical School, Boston, MA, USA) and Dr Don New-
meyer (La Jolla Institute for Allergy and Immunology), respectively.
Recombinant hu-FLAG-TRAIL was produced by co-transfecting
COS7 cells with pCDNA3.hu-FLAG-TRAIL and pCDNA3.CrmA
expression constructs. Serum-free supernatants of transfected cells
were collected after 1 week, concentrated 20-fold and used as stock
solution (approximately 50 Wg/ml hu-FLAG-TRAIL). The speci¢city
of the TRAIL-induced apoptosis was determined by inhibition of
TRAIL activity in the COS7 cell supernatants with TRAIL-R2-Fc.
2.2. Cell culture and induction of apoptosis
Cells were cultured in RPMI 1640 containing 5% foetal calf serum
(FCS). To initiate apoptosis, cells were either exposed to a UVB light
source for 20 min or incubated with indicated dilutions of culture
supernatant containing recombinant FLAG-TRAIL, in the presence
of 50^1000 ng/ml anti-FLAG antibody. Where z-VAD-fmk was used
to block caspase activity, cells were pre-incubated with the inhibitor
for 1 h prior to exposure to the apoptosis-promoting stimulus.
2.3. Flow cytometry
Apoptosis was quantitated by staining with annexin V-FITC, which
detects PS externalisation on the outer lea£et of the plasma mem-
brane, as previously described [37]. Brie£y, cells were resuspended at
106/ml in HEPES bu¡er (10 mM HEPES-NaOH, pH 7.4, 150 mM
NaCl, 5 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2) and incubated for
10 min followed by data collection on a FACScan £ow cytometer.
Changes in mitochondrial membrane potential (v8m) were measured
using DiOC6, as follows. Cells were incubated for 30 min at 37‡C in
culture medium containing 50 nM DiOC6, followed by data collection
on a FACScan £ow cytometer.
2.4. SDS^PAGE and Western blotting
Cells were lysed by incubation for 10 min at 108 cells/ml in ice-cold
lysis bu¡er (50 mM HEPES-NaOH, pH 7.2, 150 mM NaCl, 5 mM
EDTA, 0.1% NP40). Lysates were then spun at 20 000Ug for 10 min
to remove insoluble material. Protein assays (Bio-Rad, UK) were
performed to ensure that equal amounts of protein (120 Wg per
lane) were loaded on each lane of the gel. Proteins were then sepa-
rated under reducing conditions in SDS^PAGE gels, as described
previously [36,38]. Separated proteins were blotted onto nitrocellulose
membrane at 40 mA for 14 h. Blots were blocked for 1 h in TBST (10
mM Tris^HCl, pH 8, 150 mM NaCl, 0.05% Tween 20) containing 5%
non-fat dried milk and then probed for 2 h with an appropriate
amount of the primary antibody diluted in the same bu¡er. Blots
were then washed for 30 min in several changes of TBST, followed
by probing for a further 1 h with the appropriate peroxidase-coupled
secondary antibodies (Amersham, UK). Bound antibody was detected
by enhanced chemiluminescence using the Supersignal reagent (Pierce,
UK). Blots were erased for re-probing by incubation in 0.2 M NaOH
for 5 min at room temperature to strip antibodies, followed by brief
washing in TBST. Blots were then re-blocked and probed with fresh
antibody as described above.
2.5. Cytochrome c release assays
Cells (1U107) were induced to undergo apoptosis by exposure to
UV irradiation or FLAG-TRAIL and harvested at times indicated in
the appropriate ¢gure legend by centrifugation at 800Ug for 10 min.
Cell pellets were resuspended at 1^2U108 cells/ml in mannitol-sucrose
extraction bu¡er containing protease inhibitors (220 mM mannitol, 68
mM sucrose, 50 mM PIPES/KOH, pH 7.5, 50 mM KCl, 5 mM
EGTA, 2 mM MgCl2, 1 mM DTT, 1 mM PMSF, 10 Wg/ml leupeptin,
10 Wg/ml aprotinin) and after 30 min incubation on ice, were disrupted
in a Dounce homogeniser with 40 strokes of a B-type pestle. Cell
homogenates were spun at 20 000Ug for 20 min, resuspended in the
same supernatant and spun again as before. Protein assays were per-
formed on the cytosolic fractions using the Bio-Rad reagent (Bio-Rad,
UK). Equal amounts of each lysate (100^200 Wg per lane) were then
separated by SDS^PAGE and immunoblotted for cytochrome c, fol-
lowed by the re-probing of blots for other proteins where appropriate.
3. Results and discussion
3.1. TRAIL induces multiple caspase activation events in
Jurkat cells
The exposure of Jurkat T lymphoblastoid cells to recombi-
nant hu-FLAG-TRAIL, in the presence of anti-FLAG cross-
linking antibody, resulted in a dose-dependent increase in cells
undergoing morphological features of apoptosis (membrane
Fig. 1. TRAIL-induced apoptosis is caspase-dependent. A: Jurkat
cells were cultured for 6.5 h in the presence of the indicated dilu-
tions of hu-FLAG-TRAIL supernatant and 50 ng/ml crosslinking
anti-FLAG antibody, followed by assessment of annexin V-FITC
binding by £ow cytometry. B: Time course of PS externalisation in
untreated Jurkat cells or cells cultured in the presence of TRAIL
(1:1000 dilution, plus 50 ng/ml of anti-FLAG mAb) in the presence
or absence of 50 WM z-VAD-fmk. Data shown are derived from
analyses of 5000 cells at each data point and are representative of
three separate experiments.
FEBS 23513 30-3-00
S.A. Keogh et al./FEBS Letters 471 (2000) 93^9894
blebbing and DNA condensation; data not shown), as well as
exposure of PS on the outer lea£et of the plasma membrane,
as detected by annexin V binding (Fig. 1A). In the presence of
limiting amounts of anti-FLAG crosslinking antibody, the
lower concentrations of FLAG-TRAIL resulted in increased
levels of apoptosis (Fig. 1A). This is most likely because the
crosslinking of FLAG-TRAIL with limiting amounts of anti-
FLAG antibody becomes less e⁄cient when saturating
amounts of ligand are present. As expected, TRAIL-induced
apoptosis was signi¢cantly inhibited in the presence of the
broad spectrum caspase inhibitor, z-VAD-fmk (Fig. 1B), con-
¢rming that TRAIL-induced apoptosis is caspase-dependent.
To explore the range of caspase activation events initiated
in response to TRAIL receptor engagement, we probed cell
lysates from TRAIL-treated Jurkat cells with a panel of anti-
caspase antibodies. As illustrated in Fig. 2A, TRAIL treat-
ment resulted in the maturation of the zymogen forms of
caspase-2, -3, -6, -7, -8 and -9 to their corresponding pro-
cessed forms. A number of well characterised caspase sub-
strates, fodrin, gelsolin, PARP and DFF45, were also cleaved
in response to TRAIL treatment (Fig. 2B). The caspase in-
hibitor, z-VAD-fmk, blocked essentially all of these TRAIL-
induced caspase activation events, although a small amount of
caspase-8 processing was still observed in the presence of this
inhibitor suggesting that caspase-8 may be the most proxi-
mally activated caspase in this context (Fig. 2A).
3.2. TRAIL-initiated mitochondrial events
Numerous recent studies have implicated the mitochondri-
on as a key target in the program leading to collapse and
death of the cell [39^42]. Mitochondria respond to numerous
apoptosis-promoting signals by releasing pro-apoptotic mole-
cules such as cytochrome c and apoptosis-inducing factor into
the cytosol [41,43,44]. Mitochondria also exhibit a dramatic
reduction in transmembrane potential (v8m), as a result of
either partial disruption of the outer mitochondrial membrane
or the opening of discrete membrane channels [39,40,45]. To
ask whether TRAIL-initiated apoptosis was associated with
perturbations in v8m and the release of mitochondrial cyto-
chrome c, we exposed Jurkat cells to TRAIL and assessed
changes in v8m and cytosolic cytochrome c in the presence
or absence of z-VAD-fmk. As shown in Fig. 3, TRAIL-
treated Jurkat cells exhibited a dramatic reduction in v8m
that could be inhibited by z-VAD-fmk. TRAIL also triggered
the caspase-dependent release of mitochondrial cytochrome c
(Fig. 3B).
In the context of the CD95 and TNF receptor pathways, it
was recently demonstrated that cytochrome c release is insti-
gated by the Bcl-2 family member, BID [30^32]. In response
to engagement of the latter death receptors, caspase-8 is rap-
idly activated at the membrane and targets cytosolic BID for
proteolytic cleavage. Cleaved BID then translocates to the
mitochondrial membrane where it triggers cytochrome c re-
lease via a mechanism that has yet to be elucidated [30^32].
Thus, we asked whether BID also played a role in the cyto-
chrome c release seen during TRAIL-induced death. As illus-
trated in Fig. 3B,C, TRAIL-induced cytochrome c redistrib-
ution in Jurkat cells was associated with a dramatic reduction
in the levels of intact BID (the antibody used did not e⁄-
ciently recognise the cleaved form of BID). The inhibition
of caspase activity partially restored the levels of full-length
BID, in parallel with a concomitant reduction in cytochrome c
release (Fig. 3B). To con¢rm that decreases in the levels of
intact BID did not re£ect a general decrease in cellular protein
levels as cells underwent apoptosis, a time course experiment
was performed and levels of BID were compared with actin.
As illustrated in Fig. 3C, whereas BID levels decreased by
almost 50% within 3 h of exposure to TRAIL, actin expres-
sion levels did not change signi¢cantly over the same time
course.
3.3. Bcl-2 fails to regulate TRAIL-induced apoptosis in CEM
cells
Bcl-2 is capable of repressing apoptosis initiated by numer-
ous death-promoting stimuli and is thought to act primarily
within the mitochondrial outer membrane where it has been
Fig. 2. TRAIL-induced activation of multiple caspases and cleavage
of caspase substrate proteins. A: Jurkat cells were cultured for 4.5
h in medium alone, or in the presence of 50 ng/ml of hu-FLAG-
TRAIL plus 50 ng/ml of crosslinking anti-FLAG mAb. Where indi-
cated, z-VAD-fmk was also added to the medium at a ¢nal concen-
tration of 50 WM. Cell lysates were then prepared for SDS^PAGE
followed by immunoblotting for the detection of the indicated cas-
pases. Bars represent caspase pro-forms and arrows indicate pro-
cessed forms. In some cases, in order to detect the processed form
the lower portions of the blots were overexposed. In these cases, the
longer exposure is shown as a separate panel. B: Jurkat cells were
treated as in A, followed by immunoblotting for the indicated cas-
pase substrates.
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shown to regulate cytochrome c release by an unknown mech-
anism [43,44,46]. Limited evidence also suggests that Bcl-2
may be capable of acting downstream of this point under
certain circumstances [47,48]. It is not known whether Bcl-2
is capable of regulating apoptosis initiated by TRAIL receptor
ligation.
To explore this question, CEM.neo and CEM.bcl-2 cells
were compared with respect to their response to TRAIL or
exposure to UV radiation. As illustrated in Fig. 4A, Bcl-2-
expressing CEM cells were very resistant to apoptosis initiated
by UV irradiation, as well as several other stimuli, as previ-
ously reported [37,49]. However, Bcl-2 transfectants were as
sensitive to TRAIL as their vector-transfected counterparts, at
all concentrations tested (Fig. 4B,C).
3.4. TRAIL-induced cytochrome c release in CEM cells is not
regulated by Bcl-2
Because TRAIL-induced apoptosis was associated with the
redistribution of cytochrome c to the cytosol, an event that is
inhibited by Bcl-2 in the context of several other pro-apop-
totic stimuli, we asked whether the failure of Bcl-2 to regulate
TRAIL-induced apoptosis could be attributed to a failure to
block cytochrome c release. Fig. 5 illustrates that Bcl-2 failed
to block caspase-8 activation and BID cleavage in response to
TRAIL receptor engagement on CEM cells, suggesting that
these events take place upstream of the point of Bcl-2 action,
as in the CD95R and TNFR pathways. However, whereas
Bcl-2 e⁄ciently blocked UV-radiation induced cytochrome c
release, it failed to do so in cells exposed to TRAIL. These
data suggest that TRAIL engages a novel pathway leading to
cytochrome c release and apoptosis that can bypass the pro-
tective e¡ects of Bcl-2. We also assessed the Bcl-2 status in
CEM.bcl-2 cells exposed to various concentrations of TRAIL
to assess whether TRAIL receptor engagement resulted in
either phosphorylation, proteolysis or downregulation of
Bcl-2, however, no overt changes were found by Western blot-
ting (data not shown).
Here we have shown that TRAIL engages a cell death path-
way that results in multiple caspase activation events, the
cleavage of the Bcl-2 family member BID, the release of cy-
Fig. 3. TRAIL-induced mitochondrial changes, cleavage of BID and redistribution of cytochrome c are caspase-dependent. A: Jurkat cells were
incubated for 4 h either in medium alone or in the presence of hu-FLAG-TRAIL (50 ng/ml, plus 50 ng/ml anti-FLAG mAb) or hu-FLAG-
TRAIL plus 50 WM z-VAD-fmk, as indicated. Changes in mitochondrial transmembrane potential (v8m) were measured using DiOC6 uptake
in conjunction with £ow cytometry. B: Jurkat cells were treated as in A, except that cells were incubated for 6 h under the indicated condi-
tions. Cytosolic extracts were then made, mitochondria were pelleted and extracts were probed for cytochrome c, BID and caspase-3, as indi-
cated. The arrow indicates the processed form of caspase-3. C: Time course of BID cleavage in Jurkat cells cultured in the presence of hu-
FLAG-TRAIL (25 ng/ml plus 50 ng/ml anti-Flag mAb). After probing for BID, the blot was re-probed for actin to assess protein loadings.
For quantitation of BID protein levels, densitometry was performed on the blot shown using NIH-Image software. Data shown are representa-
tive of at least three experiments.
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tochrome c and the loss of mitochondrial transmembrane po-
tential. All of these events were blocked by caspase inhibitors,
suggesting that early caspase activation drives the mitochon-
drial changes that take place in the TRAIL-initiated cell death
pathway, much in the same way that these events are coordi-
nated in the Fas/CD95 and TNFR pathways. However,
TRAIL-initiated cytochrome c release and consequent apop-
tosis failed to be regulated by Bcl-2. This contrasts sharply
with what has been observed with other apoptosis-promoting
signals, such as UV radiation and staurosporine, that also
trigger cytochrome c release [43,44]. In the latter cases, Bcl-2
can block the release of cytochrome c from the mitochondrial
intermembrane space and consequently confers protection
from these agents [43,44]. This suggests that TRAIL engages
a unique pathway leading to cytochrome c release that can
bypass the inhibitory e¡ects of Bcl-2, possibly by inactivating
the latter. These data may partially explain how many tumour
cell types are uniquely susceptible to the cytotoxic e¡ects of
this cytokine.
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